Peak Perform Innova secures ~￥100M Angel Round to advance STAT6 inhibitor, PPI-101 degrader, and AI-driven PPI platform

Recently, Peak Perform Innova announced the successful completion of its angel round financing, securing nearly one hundred million. This funding round was co-led by Huagai Capital and BioTrack Capital, professional venture capital institutions deeply rooted in the healthcare sector, with participation from BOHE Angel Fund and other specialized investment firms.

The proceeds from this financing round will be primarily utilized for:

Advancing the preclinical candidate development and Investigational New Drug (IND) application for the STAT6 project, focusing on inflammatory and autoimmune diseases driven by the STAT6 signaling pathway. The aim is to deeply explore its clinical translational value and pursue a unique, differentiated development strategy.

Comprehensively advancing the IND application for PPI-101, the core degrader pipeline asset. As a first-in-class molecular glue degrader targeting RBM39, PPI-101 is focused on oncology indications with high unmet clinical needs and demonstrates significant tumor tissue penetration and anti-tumor activity.

Accelerating the rapid optimization and iteration of the AI-powered drug discovery platform focused on Protein-Protein Interactions (PPIs). This will facilitate the efficient and rational design of small-molecule PPI blockers and degraders.